Post Time: 2025-02-18
Error: No content files found.This animated video summarizes a network meta-analysis of randomized clinical trials comparing source for this article the effects of SGLT-2 inhibitors, GLP-1 agonists, and DPP-4 inhibitors on mortality in patients with type 2 diabetes. Read the article at: Key Points: Question: How do sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide 1 (GLP-1) agonists, and dipeptidyl peptidase 4 (DPP-4) click this link now inhibitors compare in reducing mortality and cardiovascular events in patients with type 2 diabetes? Findings: In this network meta-analysis that includes 236 trials with 176 310 participants, the use of SGLT-2 inhibitors or GLP-1 agonists was significantly associated with lower all-cause mortality compared with the control groups (placebo or no treatment) (hazard ratio [HR], 0.80, and HR, 0.88, respectively) and with DPP-4 inhibitors (HR, 0.78, and HR, 0.86, respectively). Meaning: In patients with type 2 diabetes, the use via of SGLT-2 inhibitors or GLP-1 agonists was associated with better mortality outcomes than DPP-4 inhibitors.